- In April 2023, Organon & Co., a global healthcare company focused on women’s health, announced the launch of a collaborative awareness initiative in partnership with local healthcare providers in Latin America to improve early diagnosis and treatment of endometriosis. The campaign includes educational programs, diagnostic support, and access to hormonal therapies, highlighting Organon’s commitment to addressing underserved gynecological conditions and expanding access to treatment across emerging markets
- In March 2023, Myovant Sciences and Pfizer Inc. received expanded regulatory approval for MYFEMBREE®, a once-daily treatment for moderate to severe endometriosis pain, in the European Union. This marks a significant advancement in non-surgical treatment options, offering improved quality of life for women living with chronic gynecological pain. The approval strengthens the companies’ joint portfolio and reflects growing investment in innovative hormonal therapies
- In March 2023, Bayer AG announced new clinical trial results for its investigational drug OCEANA—a non-hormonal therapy targeting uterine fibroids. The Phase II study demonstrated promising efficacy and safety outcomes, paving the way for further development. Bayer’s continued focus on fibroid and endometriosis research emphasizes its strategic priority to lead in women’s health through targeted drug innovation
- In February 2023, AbbVie, in collaboration with Neurocrine Biosciences, expanded the market reach of ORILISSA® and ORIAHNN® by introducing the therapies into select Asia-Pacific countries through strategic regional partnerships. These treatments offer oral, non-invasive options for managing endometriosis and uterine fibroid symptoms, aligning with the rising regional demand for advanced, accessible women’s healthcare solutions
- In January 2023, Teva Pharmaceuticals launched a generic version of a leading oral contraceptive in the U.S. market, increasing accessibility and affordability for a broad patient base. The introduction underscores the importance of generic competition in improving healthcare equity and Teva’s continued contribution to expanding treatment options within the gynecological drugs space
